News

Trump drove firing of FDA official

The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.
TipRanks on MSN4h

Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use

Shares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
Public Broadcasting Service (PBS)7h

Controversial FDA vaccine chief departs agency after less than 3 months

Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...
Healio8h

Oncologist who served as FDA’s chief medical officer, top vaccine official departs agency

A controversial hematologist-oncologist who joined FDA this spring and quickly became its top regulator has left the ...

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...
Precision Medicine Online1d

Sarepta Stock Rebounds as it Resumes Shipments of Duchenne Gene Therapy for Some Patients

The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
MedPage Today on MSN1d

Shipments of Duchenne Gene Therapy to Resume After FDA Review of Patient Death

Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver ...
GEN - Genetic Engineering and Biotechnology News2d

Sarepta to Resume Shipping DMD Gene Therapy to Ambulant Patients

Sarepta Therapeutics said it will resume shipments of its gene therapy Elevidys® (delandistrogene moxeparvovec-rokl) “imminently” to ambulant patients with Duchenne muscular dystrophy (DMD), ending a ...